Targeting RyR Activity Boosts Antisense Exon 44 and 45 Skipping in Human DMD Skeletal or Cardiac Muscle Culture Models
Systemic delivery of antisense oligonucleotides (AO) for DMD exon skipping has proven effective for reframing DMD mRNA, rescuing dystrophin expression, and slowing disease progression in animal models. In humans with Duchenne muscular dystrophy treated with AOs, low levels of dystrophin have been in...
Saved in:
Main Authors: | Florian Barthélémy (Author), Richard T. Wang (Author), Christopher Hsu (Author), Emilie D. Douine (Author), Eugene E. Marcantonio (Author), Stanley F. Nelson (Author), M. Carrie Miceli (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2019-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Repurposing Dantrolene for Long-Term Combination Therapy to Potentiate Antisense-Mediated DMD Exon Skipping in the mdx Mouse
by: Derek W. Wang, et al.
Published: (2018) -
Targeting Duchenne muscular dystrophy by skipping DMD exon 45 with base editors
by: Michael Gapinske, et al.
Published: (2023) -
Upper Limb Changes in DMD Patients Amenable to Skipping Exons 44, 45, 51 and 53: A 24-Month Study
by: Claudia Brogna, et al.
Published: (2023) -
What Can We Learn From Clinical Trials of Exon Skipping for DMD?
by: Qi-long Lu, et al.
Published: (2014) -
Efficacy of exon-skipping therapy for DMD cardiomyopathy with mutations in actin binding domain 1
by: Naoko Shiba, et al.
Published: (2023)